Lastly, the inability to firmly establish copy number alterations or assess the loss of heterozygosity with the current “standard” techniques leaves the prediction of TP53 biallelic loss to surrogates such as the detection of dual TP53 mutations, concurrent chromosome 17/17p abnormality or high mutant VAF (i.e., >50%), which have limitations when applied to TP53m-AML. The gene discussed is TP53; the disease is acute myeloid leukemia.